Kaptopriil

Kaptopriil is not a widely recognized term in pharmacology. In contemporary medical references, the spelling most commonly used is captopril, and kaptopriil is generally considered a misspelling or alternative transliteration of that name. When discussed in reliable sources, captopril is described as a first-in-class oral ACE inhibitor.

Captopril is an orally active medication used to treat hypertension and certain heart conditions. It belongs to the class of drugs known as angiotensin-converting enzyme inhibitors, which work by blocking the conversion of angiotensin I to angiotensin II. This leads to vasodilation and reduced blood pressure. Captopril also lowers afterload in heart failure and can improve survival after a myocardial infarction. It may be prescribed alone or with other antihypertensive agents.

Pharmacokinetics and administration notes indicate that captopril has relatively rapid onset when taken orally, with a half-life of a few hours and dosing typically multiple times per day. It is primarily eliminated by the kidneys, so dose adjustments may be necessary for patients with renal impairment. The drug is known to interact with certain medications and foods that can affect absorption or electrolyte balance.

Common adverse effects include cough, dizziness, hyperkalemia, and, less frequently, angioedema. A notable early effect is first-dose hypotension, particularly in patients who are salt-depleted or have been recently started on therapy. Captopril is contraindicated in pregnancy and in individuals with a history of angioedema related to previous ACE inhibitor use.

In summary, kaptopriil most often references captopril, a historically significant ACE inhibitor with a well-documented profile for treating hypertension, heart failure, and post-infarction care.